DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Google Secures Pentagon AI Deal for Classified Projects 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
NOVATO, Calif., Feb. 18, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, February 25, 2016, at 5pm ET to discuss fourth quarter and full-year 2015 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 45371417. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
